Just-Approved Cimzia Set To Enter Tough RA Market
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB vows to prove skeptics wrong with a swift, successful launch of pre-filled syringes.
You may also be interested in...
Arthritis Patient Classification To Be Key Issue In TNF Inhibitor Reviews
FDA’s Arthritis Advisory Committee will meet July 22 to give its views on how identification criteria for axial spondyloarthritis impacts approval of drugs for the disease; sBLAs seeking the indication for AbbVie’s Humira and UCB’s Cimzia are pending at the agency.
FDA's Decade Of TNF Blocker Experience Eased Path For Simponi Approval
FDA’s first-cycle approval of Centocor’s TNF inhibitor Simponi (golimumab) encapsulates the double-edged position of late entrants into crowded drug classes: while differentiating a new product may pose a commercial challenge, FDA’s experience with early members of the class can smooth the way to approval for late-comers.
FDA's Decade Of TNF Blocker Experience Eased Path For Simponi Approval
FDA’s first-cycle approval of Centocor’s TNF inhibitor Simponi (golimumab) encapsulates the double-edged position of late entrants into crowded drug classes: while differentiating a new product may pose a commercial challenge, FDA’s experience with early members of the class can smooth the way to approval for late-comers.